Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 October 2016Website:
http://www.firstwavebio.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
ENTO Latest News
New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy
What type of business is Entero Therapeutics?
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
What sector is Entero Therapeutics in?
Entero Therapeutics is in the Healthcare sector
What industry is Entero Therapeutics in?
Entero Therapeutics is in the Biotechnology industry
What country is Entero Therapeutics from?
Entero Therapeutics is headquartered in United States
When did Entero Therapeutics go public?
Entero Therapeutics initial public offering (IPO) was on 11 October 2016
What is Entero Therapeutics website?
https://www.firstwavebio.com
Is Entero Therapeutics in the S&P 500?
No, Entero Therapeutics is not included in the S&P 500 index
Is Entero Therapeutics in the NASDAQ 100?
No, Entero Therapeutics is not included in the NASDAQ 100 index
Is Entero Therapeutics in the Dow Jones?
No, Entero Therapeutics is not included in the Dow Jones index
When does Entero Therapeutics report earnings?
The next expected earnings date for Entero Therapeutics is 14 August 2024